http://www.clinicaladvisor.com/diabetes/topic/419/ Articles tagged with Diabetes from The Clinical Advisor Clinical Advisor custserv@haymarketmedia.com no Previously, the FDA has only allowed manufacturers to market HbA1c tests as tools for monitoring blood glucose, not diagnosis. http://www.clinicaladvisor.com/fda-clears-hba1c-test-for-diabetes-diagnosis/article/294750/ Fri, 24 May 2013 14:51:08 GMT Previously, the FDA has only allowed manufacturers to market HbA1c tests as tools for monitoring blood glucose, not diagnosis. Clinical Advisor Long-chain fatty acids in fish oil boost circulating adiponectin levels. http://www.clinicaladvisor.com/fish-oil-may-benefit-insulin-sensitivity/article/294493/ Wed, 22 May 2013 19:11:51 GMT Long-chain fatty acids in fish oil boost circulating adiponectin levels. Clinical Advisor Bariatric surgery may induce type 2 diabetes remission in obese patients, but more direct evidence is needed. http://www.clinicaladvisor.com/bariatric-surgery-may-reduce-type-2-diabetes-in-obese-patients/article/291077/ Tue, 30 Apr 2013 10:22:00 GMT Bariatric surgery may induce type 2 diabetes remission in obese patients, but more direct evidence is needed. Clinical Advisor Omega-3 fatty acid supplementation does not reduce mortality or cardiovascular events in patients with or at high risk for diabetes. http://www.clinicaladvisor.com/no-cv-mortality-benefit-with-omega-3-fatty-acids-in-diabetes-patients/article/291075/ Mon, 29 Apr 2013 20:53:13 GMT Omega-3 fatty acid supplementation does not reduce mortality or cardiovascular events in patients with or at high risk for diabetes. Clinical Advisor Just one 12-ounce sweet drink a day increases a person's likelihood of developing type 2 diabetes. http://www.clinicaladvisor.com/a-soda-a-day-raises-diabetes-risk-22/article/290525/ Fri, 26 Apr 2013 16:00:00 GMT Just one 12-ounce sweet drink a day increases a person's likelihood of developing type 2 diabetes. Clinical Advisor The FDA has approved canagliflozin, the first sodium-glucose co-transporter 2 inhibitor, to treat type 2 diabetes. http://www.clinicaladvisor.com/invokana-approved-for-type-2-diabetes/article/286802/ Mon, 01 Apr 2013 14:17:09 GMT The FDA has approved canagliflozin, the first sodium-glucose co-transporter 2 inhibitor, to treat type 2 diabetes. Clinical Advisor Those who transition from pediatric to adult diabetes care before the age of 21 have 2.5-fold increased odds for poor gylcemic control. http://www.clinicaladvisor.com/youth-transition-to-adult-diabetes-care-worsens-gylcemic-control/article/285928/ Mon, 25 Mar 2013 16:00:00 GMT Those who transition from pediatric to adult diabetes care before the age of 21 have 2.5-fold increased odds for poor gylcemic control. Clinical Advisor Only about 11% of the estimated 79 million Americans who had prediabetes in 2009-2010 identified as such. http://www.clinicaladvisor.com/most-americans-with-prediabetes-unaware-of-condition/article/285548/ Fri, 22 Mar 2013 19:00:00 GMT Only about 11% of the estimated 79 million Americans who had prediabetes in 2009-2010 identified as such. Clinical Advisor Results from the 2010 Global Burden of Diseases Study shows link between sugary beverage intake and mortality from chronic diseases. http://www.clinicaladvisor.com/aha-sugary-beverages-linked-to-180000-deaths-annually/article/285231/ Thu, 21 Mar 2013 14:00:00 GMT Results from the 2010 Global Burden of Diseases Study shows link between sugary beverage intake and mortality from chronic diseases. Clinical Advisor The ADA has changed systolic BP goals based on results from meta-analyses that show little additional benefit to achieving more aggressive targets. http://www.clinicaladvisor.com/revised-diabetes-guidance-raises-bp-targets/article/279300/ Wed, 06 Feb 2013 14:47:44 GMT The ADA has changed systolic BP goals based on results from meta-analyses that show little additional benefit to achieving more aggressive targets. Clinical Advisor